Trial
NCT03255083
DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Daiichi Sankyo
Collaborators
—
Condition
Non-small Cell Lung Cancer (NSCLC)
Intervention
DS-1205c
Why stopped
This study was terminated based on a business decision by the Sponsor.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-01-19